Empowering communities against AMR: Evaluating the one health-based antibiotic-wise village (SAJ

Grounds assessments

activeECDC will formally classify Candidozyma auris (formerly Candida auris) as endemic in ≥3 EU/EEA countries via a technical report, surveillance update, or risk assessment by 2026-10-17, formalizing the trajectory described in Medscape 2026-04-13 ("C auris Is Now Endemic in Europe. Can It Be Contained?") and CIDRAP 2025-09-11 ("Multidrug-resistant yeast cases rising rapidly in Europe, survey shows").60%activetetM-carrying N. gonorrhoeae prevalence in US surveillance reaches ≥30% by EOY 2026 OR ≥3 independent confirmed extensively drug-resistant (ceftriaxone+azithromycin+ciprofloxacin simultaneously resistant) N. gonorrhoeae transmission clusters documented in US/EU/AU during 2026, threatening the doxyPEP era and last-line cephalosporin therapy.60%activeCDC will publish a Morbidity and Mortality Weekly Report (MMWR) early release or health advisory specifically characterizing XDR Shigella (azithromycin + fluoroquinolone + 3GC resistant) geographic spread and treatment guidance within 60 days of the April 13 2026 emergence report (by June 12 2026), consistent with CDC's precedent of issuing MMWR early releases for novel drug-resistant Shigella phenotypes (2022-2023 ceftriaxone-resistant Shigella MMWR).60%expiredAt least one XDR Shigella case with genomic linkage to the US April 2026 emergence cluster will be confirmed in Australia, Canada, or Japan within 120 days (by August 13 2026), based on high-frequency MSM travel networks connecting these countries to the US, and the historical 2022-2023 pattern where drug-resistant Shigella reached high-income Pacific Rim countries within 8 months of initial US detection.40%expiredXDR Shigella (extensively drug-resistant, resistant to azithromycin + fluoroquinolones + 3GC) will establish sustained community transmission in at least 3 US states within 12 months of CDC's April 2026 emergence report, requiring updated CDC treatment guidance and triggering enhanced surveillance protocols.40%

Evidence content

Empowering communities against AMR: Evaluating the one health-based antibiotic-wise village (SAJ — research event update (updated 2026-04-13T00:52)

Empowering communities against AMR: Evaluating the one health-based antibiotic-wise village (SAJ

Field	Value
date	2026-04-13
event_type	pubmed
headline	Empowering communities against AMR: Evaluating the one health-based antibiotic-wise village (SAJ
research_domain	generic
scope	amr
source_meta	{"source":{"sourceId":"pubmed","name":"PubMed","tier":"T2","url":"https://pubmed.ncbi.nlm.nih.gov","documentUrl":"https://pubmed.ncbi.nlm.nih.gov/41665178/","documentTitle":"Empowering communities against AMR: Evaluating the one health-based antibiotic-wise village (SAJAKA) in Bali, Indonesia."},"hypothesisLinks":[],"flags":["unverified"],"direction":"neutral","relevanceScore":0.1,"publishedAt":"2026-02-10T00:00:00.000Z","metadata":{"pmid":"41665178","journal":"Global public health","extractionMethod":"eutils","query":"(H5N1 OR influenza OR coronavirus OR mpox OR "antimicrobial resistance" OR dengue OR zika OR chikungunya)","classification":{"strategy":"keyword-v1","scopeId":"amr","hypothesisMatches":0,"scopeRelevance":0.09302325581395349}}}
source_url	https://pubmed.ncbi.nlm.nih.gov/41665178/
summary	Empowering communities against AMR: Evaluating the one health-based antibiotic-wise village (SAJAKA) in Bali, Indonesia.. Antimicrobial resistance (AMR) is a critical global health issue, especially in low-resource settings. A One Health-based community engagement approach, such as the Antibiotic-Wise Village (SAJAKA) model, offers a potential solution.

Technical metadataPipeline attribution for verification

Connector: —
Payload kind: —
Run ID: —
Schema version: —

Assessment unavailable

This assessment could not be loaded right now because no recent cached snapshot is available.